Pincus Theodore, Wang Xiaofei, Chung Cecilia, Sokka Tuulikki, Koch Gary G
Division of Rheumatology and Immunology, Vanderbilt University School of Medicine, 203 Oxford House, Box 5, Nashville, TN 37232, USA.
J Rheumatol. 2005 Mar;32(3):533-9.
To analyze correlational validity of self-report responses regarding patient preference between 2 drugs at the conclusion of a crossover double-blind clinical trial in patients with osteoarthritis (OA) of the knee or hip.
Patients were randomized to 6 weeks' treatment of diclofenac/misoprostol or acetaminophen, followed by crossover to 6 weeks of the other drug. Patient preference was queried at the final visit: "Please compare control of your arthritis during the first and second periods as 'much better' or 'better' in the first period, 'no different' or 'better' or 'much better' in the second period." Patient preference ratings were evaluated in comparisons with 4 independent self-report measures within each treatment period: (1) change in Western Ontario McMaster (WOMAC) questionnaire scores; (2) change in pain visual analog scale (VAS) on a multidimensional Health Assessment Questionnaire (MDHAQ); (3) patient ratings of drug efficacy; and (4) patient report of change in arthritis status, as well as investigator ratings of the more efficacious drug.
Among 173 patients, diclofenac/misoprostol was rated as "much better" by 54 and "better" by 45, acetaminophen was rated as "better" by 18 and "much better" by 17, and "no difference" by 39 patients. Spearman rank correlations for patient preferences were significant for changes in WOMAC scores, pain VAS, and independent patient ratings of drug efficacy and changes in arthritis status within each treatment period, as well as with physician ratings of the more efficacious drug (p < 0.001).
Significant correlational validity is documented for patient self-report of preferences between 2 drugs compared to independent measures within each treatment period in this crossover clinical trial in patients with OA of the knee or hip.
在一项针对膝关节或髋关节骨关节炎(OA)患者的交叉双盲临床试验结束时,分析关于两种药物患者偏好的自我报告应答的相关性效度。
患者被随机分配接受双氯芬酸/米索前列醇或对乙酰氨基酚治疗6周,随后交叉接受另一种药物治疗6周。在最后一次访视时询问患者偏好:“请比较你在第一个和第二个治疗期的关节炎控制情况,第一个治疗期为‘好得多’或‘更好’,第二个治疗期为‘无差异’或‘更好’或‘好得多’。”在每个治疗期内,将患者偏好评分与4项独立的自我报告指标进行比较评估:(1)西安大略和麦克马斯特大学(WOMAC)问卷评分的变化;(2)多维健康评估问卷(MDHAQ)上疼痛视觉模拟量表(VAS)的变化;(3)患者对药物疗效的评分;(4)患者报告的关节炎状态变化,以及研究者对更有效药物的评分。
在173例患者中,54例将双氯芬酸/米索前列醇评为“好得多”,45例评为“更好”,18例将对乙酰氨基酚评为“更好”,17例评为“好得多”,39例患者评为“无差异”。患者偏好的Spearman等级相关性在每个治疗期内WOMAC评分变化、疼痛VAS、患者对药物疗效的独立评分以及关节炎状态变化方面均具有显著性,并且与医生对更有效药物的评分也具有显著性(p<0.001)。
在这项针对膝关节或髋关节OA患者的交叉临床试验中,与每个治疗期内的独立测量指标相比,患者对两种药物偏好的自我报告具有显著的相关性效度。